Characteristics of patients with NSCLC treated with ICIs included in the Rome cohort (n=35)
| Characteristics | N (%) |
| Age at diagnosis | |
| Median (IQR) | 64.08 (42.20–75.61) |
| Gender | |
| Male | 21 (60.0) |
| Female | 14 (40.0) |
| Histology | |
| LAC | 27 (77.1) |
| LSCC | 8 (22.9) |
| Smoking status | |
| Ever | 30 (85.7) |
| Never | 5 (14.3) |
| Performance status | |
| 0 | 26 (74.3) |
| 1 | 9 (25.7) |
| ICI line of treatment | |
| First | 19 (54.3) |
| Second | 14 (40.0) |
| Third | 2 (5.7) |
| PD-L1 (IHC) | |
| ≥50% | 16 (45.7) |
| 1%–49% | 10 (28.6) |
| negative | 9 (25.7) |
| TMB | |
| Low | 9 (25.7) |
| Intermediate | 21 (60.0) |
| Not available | 5 (14.3) |
| Treatment | |
| Pembrolizumab | 24 (68.6) |
| Atezolizumab | 7 (20.0) |
| Nivolumab | 4 (11.4) |
| HPD | |
| No | 29 (82.9) |
| Yes | 6 (17.1) |
HPD, hyperprogressive disease; ICI, immune checkpoint inhibitor; IHC, immunohistochemistry; LAC, lung adenocarcinoma; LSCC, lung squamous cell carcinoma; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; TMB, tumor mutational burden.